The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by Cantor Fitzgerald on September 23, 2024. The analyst firm set a price target for $65.00 expecting GPCR to rise to within 12 months (a possible 48.87% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Structure Therapeutics (NASDAQ:GPCR) was provided by Cantor Fitzgerald, and Structure Therapeutics reiterated their overweight rating.

There is no last upgrade for Structure Therapeutics

There is no last downgrade for Structure Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Structure Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Structure Therapeutics was filed on September 23, 2024 so you should expect the next rating to be made available sometime around September 23, 2025.

While ratings are subjective and will change, the latest Structure Therapeutics (GPCR) rating was a reiterated with a price target of $65.00 to $65.00. The current price Structure Therapeutics (GPCR) is trading at is $43.66, which is out of the analyst’s predicted range.